Abstract:ABSTRACT A recent demonstration of synergy between a temperate phage and the antibiotic ciprofloxacin suggested a scalable approach to exploiting temperate phages in therapy, termed temperate phage-antibiotic synergy, which specifically interacted with the lysis-lysogeny decision. To determine whether this would hold true across antibiotics, we challenged Escherichia coli with the phage HK97 and a set of 13 antibiotics spanning seven classes. As expected, given the conserved induction pathway, we observed synergy with classes of drugs known to induce an SOS response: a sulfa drug, other quinolones, and mitomycin C. While some β-lactams exhibited synergy, this appeared to be traditional phage-antibiotic synergy, with no effect on the lysis-lysogeny decision. Curiously, we observed a potent synergy with antibiotics not known to induce the SOS response: protein synthesis inhibitors gentamicin, kanamycin, tetracycline, and azithromycin. The synergy results in an eightfold reduction in the effective minimum inhibitory concentration of gentamicin, complete eradication of the bacteria, and, when administered at sub-optimal doses, drastically decreases the frequency of lysogens emerging from the combined challenge. However, lysogens exhibit no increased sensitivity to the antibiotic; synergy was maintained in the absence of RecA; and the antibiotic reduced the initial frequency of lysogeny rather than selecting against formed lysogens. Our results confirm that SOS-inducing antibiotics broadly result in temperate-phage-specific synergy, but that other antibiotics can interact with temperate phages specifically and result in synergy. This is the first report of a means of chemically blocking entry into lysogeny, providing a new means for manipulating the key lysis-lysogeny decision. IMPORTANCE The lysis-lysogeny decision is made by most bacterial viruses (bacteriophages, phages), determining whether to kill their host or go dormant within it. With over half of the bacteria containing phages waiting to wake, this is one of the most important behaviors in all of biology. These phages are also considered unusable for therapy because of this behavior. In this paper, we show that many antibiotics bias this behavior to “wake” the dormant phages, forcing them to kill their host, but some also prevent dormancy in the first place. These will be important tools to study this critical decision point and may enable the therapeutic use of these phages.

The phage anti-restriction induced system: new insights into bacterial immunity and bacteriophage escape strategies

The arms race between bacteria and their phage foes

Diversified repertoire of phage resistance in and bidirectional steering effects impacting antibiotic susceptibility

Phage therapy: A targeted approach to overcoming antibiotic resistance

The novel anti-phage system Shield co-opts an RmuC domain to mediate phage defense across Pseudomonas species

BacteRiophage EXclusion (BREX): A novel anti‐phage mechanism in the arsenal of bacterial defense system

Phage therapy: From biological mechanisms to future directions

An enterococcal phage protein broadly inhibits type IV restriction enzymes involved in antiphage defense

Virulence-associated factors as targets for phage infection

An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense

Systematic Discovery of Phage Genes that Inactivate Bacterial Immune Systems

Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection

Phage-induced efflux down-regulation boosts antibiotic efficacy

Bacterial Receptors but Not Anti-Phage Defence Mechanisms Determine Host Range for a Pair of Lytic Phages

Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages

Current and future directions in bacteriophage research for developing therapeutic innovations

Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny

Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions

Directed Evolution of Replication-Competent Double-Stranded DNA Bacteriophage Toward New Host Specificity.

Inhibitors of bacterial immune systems: discovery, mechanisms and applications

Turning down the (C)BASS: Phage-encoded inhibitors jam bacterial immune signaling